Skip to main content
Journal cover image

Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy.

Publication ,  Journal Article
Petit, T; Wilt, M; Velten, M; Millon, R; Rodier, J-F; Borel, C; Mors, R; Haegelé, P; Eber, M; Ghnassia, J-P
Published in: Eur J Cancer
January 2004

The aim of this study was to evaluate the predictive value of five different biological factors in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy: (1) tumour grade scored according to the Elston-Ellis classification, (2) hormonal receptor (HR) status; (3) tumour cell proliferation evaluated by Ki-67 staining, (4) HER-2 and topoisomerase II alpha (TopoIIalpha) expression evaluated by immunohistochemistry (IHC), (5) HER-2 and TopoIIalpha amplification evaluated by real-time polymerase chain reaction (PCR). 119 patients with operable breast cancer were treated with six cycles of FEC (100 5-fluorouracil (5-FU) 500 mg/m2, Epirubicin 100 mg/m2, Cyclophosphamide 500 mg/m2). Tumour response was assessed clinically and by computed tomography (CT) scan, then by pathological assessment. The clinical overall response (OR) was 80%, with 19% of complete responders (CR). The radiological OR was 71%, with 16% of CR. A pathological CR was demonstrated in 13% of the patients according to the Sataloff classification. In the multivariate analysis, the absence of HR expression and Ki-67 > or = 20% were predictive for a clinical CR. A high tumour grade was predictive for a pathological CR. Overexpression or amplification of HER2 or Topollcalpha were not predictive of response.

Duke Scholars

Published In

Eur J Cancer

DOI

ISSN

0959-8049

Publication Date

January 2004

Volume

40

Issue

2

Start / End Page

205 / 211

Location

England

Related Subject Headings

  • Receptors, Cell Surface
  • Receptor, erbB-2
  • Receptor, ErbB-2
  • Polymerase Chain Reaction
  • Oncology & Carcinogenesis
  • Middle Aged
  • Ki-67 Antigen
  • Humans
  • Hormones
  • Fluorouracil
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Petit, T., Wilt, M., Velten, M., Millon, R., Rodier, J.-F., Borel, C., … Ghnassia, J.-P. (2004). Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. Eur J Cancer, 40(2), 205–211. https://doi.org/10.1016/s0959-8049(03)00675-0
Petit, T., M. Wilt, M. Velten, R. Millon, J. -. F. Rodier, C. Borel, R. Mors, P. Haegelé, M. Eber, and J. -. P. Ghnassia. “Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy.Eur J Cancer 40, no. 2 (January 2004): 205–11. https://doi.org/10.1016/s0959-8049(03)00675-0.
Petit T, Wilt M, Velten M, Millon R, Rodier J-F, Borel C, Mors R, Haegelé P, Eber M, Ghnassia J-P. Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. Eur J Cancer. 2004 Jan;40(2):205–211.
Journal cover image

Published In

Eur J Cancer

DOI

ISSN

0959-8049

Publication Date

January 2004

Volume

40

Issue

2

Start / End Page

205 / 211

Location

England

Related Subject Headings

  • Receptors, Cell Surface
  • Receptor, erbB-2
  • Receptor, ErbB-2
  • Polymerase Chain Reaction
  • Oncology & Carcinogenesis
  • Middle Aged
  • Ki-67 Antigen
  • Humans
  • Hormones
  • Fluorouracil